You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Reassurance, Refunds & Replacements

If your product does not perform as described on this datasheet, we will refund or replace your product...

Read our guarantee »
 

Anti-PSAP antibody [PASE/4LJ] - BSA and Azide free (ab80717)

CodeSizePriceAbpointsAvailability
    
 
  • -
  •   
  •   
  •   
  •  
  •   
  •   
Updating...

Overview

Product name

Anti-PSAP antibody [PASE/4LJ] - BSA and Azide free
See all PSAP products (6) ...

Description

Mouse monoclonal [PASE/4LJ] to PSAP - BSA and Azide free

Specificity

This antibody does not inhibit the enzymatic activity of PSAP. It reacts with non-neoplastic adult and fetal prostatic glands, primary and metastatic prostatic carcinomas. It shows no cross reaction with other phosphatases.

Tested applications

IHC-P, ICC/IFmore details

Cross reactivity

Reacts with

Human

Does not react with

Rat, Rabbit, Dog

Immunogen

Purified PSAP from Human seminal plasma.

Positive control

Normal prostate or prostate carcinoma.

Properties

Form

Liquid

Storage instructions

Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

Storage buffer

Preservative: None
Constituents: 10mM PBS, pH 7.4

Concentration

Concentration information loading...

Purity

Protein G purified

Purification notes

Purified from culture supernatant by Protein G chromatography.

Clonality

Monoclonal

Clone number

PASE/4LJ

Isotype

IgG1

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - PSAP antibody [PASE/4LJ] - BSA and Azide free (ab80717)Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - PSAP antibody [PASE/4LJ] - BSA and Azide free (ab80717) image (enlarge)

Applications

Show applications key

Our Abpromise guarantee covers the use of ab80717 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • 1 Image

    IHC-P

     IHC-P: 1/1500

    IHC-P: 1/1500

  • ShowHide

    ICC/IF

     ICC/IF: Use at an assay ...Read more →

    ICC/IF: Use at an assay dependent dilution.

Target

Function

The lysosomal degradation of sphingolipids takes place by the sequential action of specific hydrolases. Some of these enzymes require specific low-molecular mass, non-enzymic proteins: the sphingolipids activator proteins (coproteins).
Saposin-A and saposin-C stimulate the hydrolysis of glucosylceramide by beta-glucosylceramidase (EC 3.2.1.45) and galactosylceramide by beta-galactosylceramidase (EC 3.2.1.46). Saposin-C apparently acts by combining with the enzyme and acidic lipid to form an activated complex, rather than by solubilizing the substrate.
Saposin-B stimulates the hydrolysis of galacto-cerebroside sulfate by arylsulfatase A (EC 3.1.6.8), GM1 gangliosides by beta-galactosidase (EC 3.2.1.23) and globotriaosylceramide by alpha-galactosidase A (EC 3.2.1.22). Saposin-B forms a solubilizing complex with the substrates of the sphingolipid hydrolases.
Saposin-D is a specific sphingomyelin phosphodiesterase activator (EC 3.1.4.12).

Involvement in disease

Defects in PSAP are the cause of combined saposin deficiency (CSAPD) [MIM:611721]; also known as prosaposin deficiency. CSAPD is due to absence of all saposins, leading to a fatal storage disorder with hepatosplenomegaly and severe neurological involvement.
Defects in PSAP saposin-B region are the cause of leukodystrophy metachromatic due to saposin-B deficiency (MLD-SAPB) [MIM:249900]. MLD-SAPB is an atypical form of metachromatic leukodystrophy. It is characterized by tissue accumulation of cerebroside-3-sulfate, demyelination, periventricular white matter abnormalities, peripheral neuropathy. Additional neurological features include dysarthria, ataxic gait, psychomotr regression, seizures, cognitive decline and spastic quadriparesis.
Defects in PSAP saposin-C region are the cause of atypical Gaucher disease (AGD) [MIM:610539]. Affected individuals have marked glucosylceramide accumulation in the spleen without having a deficiency of glucosylceramide-beta glucosidase characteristic of classic Gaucher disease, a lysosomal storage disorder.
Defects in PSAP saposin-A region are the cause of atypical Krabbe disease (AKRD) [MIM:611722]. AKRD is a disorder of galactosylceramide metabolism. AKRD features include progressive encephalopathy and abnormal myelination in the cerebral white matter resembling Krabbe disease.
Note=Defects in PSAP saposin-D region are found in a variant of Tay-Sachs disease (GM2-gangliosidosis).

Sequence similarities

Contains 2 saposin A-type domains.
Contains 4 saposin B-type domains.

Post-translational
modifications

This precursor is proteolytically processed to 4 small peptides, which are similar to each other and are sphingolipid hydrolase activator proteins.
N-linked glycans show a high degree of microheterogeneity.
The one residue extended Saposin-B-Val is only found in 5% of the chains.

Cellular localization

Lysosome.

Target information above from: UniProt accessionP07602 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).

Information by UniProt

Alternative names

  • A1 activator antibody
  • Cerebroside sulfate activator antibody
  • Co-beta-glucosidase antibody
  • Component C antibody
  • CSAct antibody
  • Dispersin antibody
  • GLBA antibody
  • Glucosylceramidase activator antibody
  • Proactivator polypeptide antibody
  • Proactivator polypeptide precursor antibody
  • Prosaposin (sphingolipid activator protein 1) antibody
  • prosaposin (variant Gaucher disease and variant metachromatic leukodystrophy) antibody
  • Protein A antibody
  • Protein C antibody
  • PSAP antibody
  • SAP-1 antibody
  • SAP-2 antibody
  • SAP_HUMAN antibody
  • SAP1 antibody
  • Saposin A antibody
  • Saposin B antibody
  • Saposin B Val antibody
  • Saposin C antibody
  • Saposin D antibody
  • Saposin-D antibody
  • Saposins antibody
  • Sphingolipid activator protein 1 antibody
  • Sphingolipid activator protein 2 antibody
  • Sulfatide/GM1 activator antibody
see all

Anti-PSAP antibody [PASE/4LJ] - BSA and Azide free images:

  Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - PSAP antibody [PASE/4LJ] - BSA and Azide free (ab80717)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - PSAP antibody [PASE/4LJ] - BSA and Azide free (ab80717)

Formalin-fixed, paraffin-embedded human prostate stained with ab80717 at a 1/1500 dilution using alkaline phosphatase-conjugate and fast red chromogen. Note intense cytoplasmic staining of glandular epithelial cells.

References for Anti-PSAP antibody [PASE/4LJ] - BSA and Azide free (ab80717)

This product has been referenced in:

  • Haines AMet al. A novel hybridoma antibody (PASE/4LJ) to human prostatic acid phosphatase suitable for immunohistochemistry. Br J Cancer 60:887-92 (1989). ICC/IF, IHC-P; Human.Read more (PubMed: 2605098) »

See 1 publication for this product

Publishing research using ab80717? Please let us know so that we can cite the reference in this datasheet

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"